Evaluation of the scientific basis for the use of riamilovir for the treatment of COVID-19


DOI: https://dx.doi.org/10.18565/pharmateca.2021.1.14-16

K.B. Mirzaev (1), V.M. Tsvetov (2)

1) Russian Medical Academy of Continuous Professional Education, Moscow, Russia, https://orcid.org/0000-0002-9307-4994; 2) Federal Center for Cardiovascular Surgery, Chelyabinsk, Russia, https://orcid.org/0000-0003-4810-2295
To date, the results of one incompleted clinical trial evaluating the efficacy and safety of riamilovir for patients with COVID-19, as well as the results of a generalized experience of use the drug without a control group and randomization of patients have been published. This trial did not reveal the benefits of using the drug. The study of the use of riamilovir in the treatment of hospitalized patients with laboratory-confirmed mild to moderate COVID-19 is ongoing.
Keywords: COVID-19, riamilovir

Бионика Медиа